Suppr超能文献

欧洲皮肤病与性病学会/欧洲变态反应与临床免疫学会湿疹工作组2020年关于成人和儿童特应性皮炎诊断与治疗的立场文件。

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

作者信息

Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen J P, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork M J, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen D J, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder J F, Ring J

机构信息

Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany.

Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

出版信息

J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2717-2744. doi: 10.1111/jdv.16892. Epub 2020 Nov 17.

Abstract

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient's age and also target flare prevention. Basic therapy includes hydrating and barrier-stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti-inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid-potency corticosteroids are proven agents for proactive therapy, which is defined as the long-term intermittent anti-inflammatory therapy of frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is a rapidly changing field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit-risk ratio. The IL-4R-blocker dupilumab is a safe, effective and licensed, but expensive, treatment option with potential ocular side-effects. Other biologicals targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) only have limited effects on AD-related itch and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be useful for atopic hand and foot eczema. Dietary recommendations should be patient-specific, and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. Efficacy-proven 'Eczema school' educational programmes and therapeutic patient education are recommended for both children and adults.

摘要

特应性皮炎(AD)是一种高度瘙痒的慢性炎症性皮肤病。诊断依据评估后的临床标准进行。疾病活动度和负担最好通过综合评分来衡量,该评分同时评估客观和主观症状,如特应性皮炎评分(SCORAD)。AD的管理必须考虑临床和致病因素的变异性、患者年龄,同时以预防病情复发为目标。基础治疗包括普遍应用的保湿和稳定皮肤屏障的局部治疗,以及避免特定和非特定的诱发因素。可见的皮肤损害用抗炎局部用药治疗,如皮质类固醇和钙调神经磷酸酶抑制剂(他克莫司和吡美莫司),这些药物在敏感部位更为适用。外用他克莫司和一些中效皮质类固醇是经证实的用于主动治疗的药物,主动治疗定义为对频繁复发的皮肤区域进行长期间歇性抗炎治疗。全身抗炎或免疫抑制治疗是一个快速变化的领域,需要进行监测。口服皮质类固醇的效益风险比在很大程度上不利。白细胞介素-4受体阻滞剂度普利尤单抗是一种安全、有效且已获许可的治疗选择,但价格昂贵,且有潜在的眼部副作用。其他针对特应性免疫反应关键途径的生物制剂以及不同的 Janus 激酶抑制剂属于新兴的治疗选择。微生物定植和感染失衡可能导致病情加重,这可以作为额外抗菌治疗的依据。全身性抗组胺药(H1R 阻滞剂)对AD相关的瘙痒和湿疹皮损仅有有限的作用。辅助治疗包括紫外线照射,最好是窄谱中波紫外线或长波紫外线1。煤焦油可能对特应性手足湿疹有用。饮食建议应因人而异,只有在证实食物过敏的情况下才建议进行排除饮食。对空气过敏原进行的变应原特异性免疫治疗在某些特定病例中可能有用。建议进行心身咨询以应对压力诱发的病情加重。对于儿童和成人,推荐经过疗效验证的“湿疹学校”教育项目和治疗性患者教育。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验